Wednesday, April 2, 2025 4/2/2025

High-density flagellin-displayed virus-like particle for universal influenza vaccine development'

Award Number: R21AI156510
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

High-density flagellin-displayed virus-like particle for universal influenza vaccine development' - Project Summary/Abstract Current influenza vaccines mainly induce strain-specific protection. Universal influenza vaccines are under active development to induce broad cross-protection. Extracellular ectodomain of matrix protein 2 (M2e) and intracellular nucleoprotein (NP) are highly conserved across viral strains and are attractive targets in universal influenza vaccine development. Various preclinical and clinical studies support the induction of anti-M2e antibodies and anti-NP cytotoxic T lymphocytes (CTLs) to induce broad cross-protective immunity. Due to the low immunogenicity of M2e and NP, highly immunogenic vaccine carriers are demanded to present these conserved vaccine antigens to induce potent cross-reactive immune responses. This proposal explores our recently developed high-density flagellin-displayed hepatitis b core (HBc) virus-like particles (VLPs) (FH VLPs) in combination with a clinical CpG adjuvant (FHc VLPs) for universal influenza vaccine development. FH VLPs show better immunogenicity and safety than FljB and more versatility than HBc VLPs for vaccine development. Furthermore, a clinical CpG adjuvant will be encapsulated into the core of FH VLPs to potentiate vaccine- induced humoral immune responses and at the same time to induce potent CTL responses. This proposal prepares M2e and NP-displayed FHc VLP-based universal influenza vaccines (Specific aim 1) and explore their safety, immunogenicity, and cross-protective efficacy in murine models (Specific aim 2). This proposal is in response to National Institute of Allergy and Infectious Diseases (NIAID)'s call for Advancing Research Needed to Develop a Universal Influenza Vaccine (PA-18-858).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	UNIVERSITY OF RHODE ISLAND	75 LOWER COLLEGE RD RM 103	KINGSTON	RI	02881	WASHINGTON	USA	Allergy and Infectious Diseases Research	000	2	1/16/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $236,250 )
2022	2022	UNIVERSITY OF RHODE ISLAND	75 LOWER COLLEGE	KINGSTON	RI	02881	WASHINGTON	USA	Allergy and Infectious Diseases Research	000	2	5/9/2022	NON-COMPETING CONTINUATION	$236,250
														Subtotal = $236,250

Issue Date FY: 2021 ( Subtotal = $196,875 )
2021	2021	UNIVERSITY OF RHODE ISLAND	75 LOWER COLLEGE	KINGSTON	RI	02881	WASHINGTON	USA	Allergy and Infectious Diseases Research	000	1	6/11/2021	NEW	$196,875
														Subtotal = $196,875

Grand Total All Awards = $433,125

Top

All Categories

About

Search

Reports

Data Submission

Award Information

High-density flagellin-displayed virus-like particle for universal influenza vaccine development'

Award Number: R21AI156510

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer